Novo Nordisk CEO explains decision to discontinue the long-acting insulin Levemir. He blamed pharmacy managers and health ...

Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for ...

Novo Nordisk CEO Lars Fruergaard Jorgensen testified before the Senate Health, Education, Labor and Pensions Committee hearing in ...

Novo Nordisk CEO Lars Fruergaard Jørgensen faces a Senate hearing led by Bernie Sanders over the high cost of Ozempic and ...

Novo Nordisk CEO Lars Fruergaard Jørgensen testified before the Senate Health, Education, Labor and Pension committee on ...

CEO Lars Fruergaard Jørgensen agreed today, during a Senate committee hearing, to sit down with lawmakers and pharmacy ...

Sen. Bernie Sanders argues that Novo Nordisk charges Americans substantially higher prices for its drugs than it does for ...

Senate HELP Chairman Bernie Sanders launches another salvo in drug pricing war, this one aimed at popular weight loss drugs.

Novo Nordisk CEO grilled over company's pricing for the diabetes drug Ozempic and the weight-loss drug Wegovy.

CEO Lars Fruergaard Jorgenson has been grilled by a U.S. Senate Committee over the high-cost of the company’s diabetes and ...

Coverage for its long-acting insulin, Levamir, dropped from 90% to about 35% when the company dropped its list price by 65%.

Novo Nordisk CEO Lars Fruergaard Jørgensen is testifying before the Senate Health, Education, Labor and Pension committee on ...